PriceTargets.com logo

Haemonetics - HAE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $79.70
  • Forecasted Upside: -4.87%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$83.78 As of 12/4/2025 04:59 PM ET
▲ +1.87 (2.28%)

This chart shows the closing price for HAE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Haemonetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HAE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HAE

Analyst Price Target is $79.70
▼ -4.87% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $79.70, with a high forecast of $100.00 and a low forecast of $62.00. The average price target represents a -4.87% upside from the last price of $83.78.

This chart shows the closing price for HAE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in Haemonetics. This rating has held steady since August 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/25/2025Weiss RatingsUpgradeSell (D+) ➝ Hold (C-)
11/21/2025BTIG ResearchReiterated RatingBuy ➝ Buy$88.00
11/14/2025Raymond James FinancialReiterated RatingOutperform ➝ Outperform$90.00
11/7/2025Barrington ResearchBoost TargetOutperform ➝ Outperform$86.00 ➝ $90.00
11/7/2025Needham & Company LLCBoost TargetBuy ➝ Buy$68.00 ➝ $78.00
11/6/2025BTIG ResearchBoost TargetBuy ➝ Buy$85.00 ➝ $88.00
10/25/2025Weiss RatingsDowngradeHold (C-) ➝ Sell (D+)
10/21/2025Barrington ResearchReiterated RatingOutperform ➝ Outperform$86.00
10/8/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
10/7/2025CitigroupLower TargetBuy ➝ Buy$78.00 ➝ $64.00
9/27/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/23/2025Barrington ResearchReiterated RatingOutperform ➝ Outperform$86.00
8/11/2025Raymond James FinancialDowngradeStrong-Buy ➝ Outperform$105.00 ➝ $78.00
8/8/2025JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$85.00 ➝ $62.00
8/8/2025MizuhoLower TargetOutperform ➝ Outperform$90.00 ➝ $70.00
8/8/2025Barrington ResearchLower TargetOutperform ➝ Outperform$95.00 ➝ $86.00
8/7/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$84.00 ➝ $68.00
7/11/2025Barrington ResearchReiterated RatingOutperform ➝ Outperform$95.00
7/9/2025CitigroupUpgradeNeutral ➝ Buy$90.00
6/26/2025Robert W. BairdInitiated CoverageOutperform$87.00
6/25/2025Baird R WUpgradeStrong-Buy
5/20/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$100.00 ➝ $100.00
5/9/2025Raymond James FinancialReiterated RatingStrong-Buy ➝ Strong-Buy$115.00 ➝ $105.00
5/8/2025Needham & Company LLCLower TargetBuy ➝ Buy$104.00 ➝ $84.00
3/18/2025Needham & Company LLCLower TargetBuy ➝ Buy$108.00 ➝ $104.00
2/7/2025Raymond James FinancialReiterated RatingStrong-Buy ➝ Strong-Buy$120.00 ➝ $115.00
2/7/2025JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$125.00 ➝ $100.00
2/7/2025Needham & Company LLCLower TargetBuy ➝ Buy$112.00 ➝ $108.00
2/7/2025Bank of AmericaDowngradeNeutral ➝ Underperform$95.00 ➝ $68.00
2/7/2025Barrington ResearchLower TargetOutperform ➝ Outperform$108.00 ➝ $95.00
12/6/2024JPMorgan Chase & Co.Initiated CoverageOverweight$116.00
12/4/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$108.00 ➝ $108.00
12/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$112.00 ➝ $112.00
11/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$112.00 ➝ $112.00
11/8/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$108.00 ➝ $108.00
11/8/2024Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$120.00 ➝ $120.00
9/23/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$108.00 ➝ $108.00
9/13/2024CL KingInitiated CoverageBuy$116.00
9/11/2024Bank of AmericaInitiated CoverageNeutral$85.00
9/10/2024BTIG ResearchInitiated CoverageBuy$112.00
8/22/2024CitigroupLower TargetNeutral ➝ Neutral$94.00 ➝ $85.00
8/13/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$125.00 ➝ $125.00
8/9/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$107.00 ➝ $108.00
6/12/2024Needham & Company LLCUpgradeHold ➝ Buy$112.00
5/10/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$115.00 ➝ $125.00
5/10/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$105.00 ➝ $107.00
5/10/2024Needham & Company LLCReiterated RatingHold
4/12/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$105.00
2/13/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$105.00
11/3/2023Barrington ResearchLower TargetOutperform ➝ Outperform$114.00 ➝ $105.00
10/2/2023CitigroupBoost TargetNeutral ➝ Neutral$90.00 ➝ $94.00
8/9/2023Barrington ResearchBoost TargetOutperform ➝ Outperform$111.00 ➝ $114.00
5/12/2023Barrington ResearchBoost Target$103.00 ➝ $111.00
5/12/2023JMP SecuritiesBoost Target$105.00 ➝ $115.00
4/3/2023CitigroupLower Target$95.00 ➝ $90.00
2/8/2023CitigroupBoost TargetNeutral$92.00 ➝ $95.00
2/8/2023Morgan StanleyBoost TargetEqual Weight$84.00 ➝ $88.00
2/8/2023Barrington ResearchBoost TargetOutperform$94.00 ➝ $103.00
2/8/2023MizuhoBoost TargetBuy$110.00 ➝ $115.00
1/24/2023MizuhoBoost TargetBuy$100.00 ➝ $110.00
1/6/2023Morgan StanleyLower TargetEqual Weight$90.00 ➝ $84.00
12/12/2022CitigroupBoost TargetNeutral$88.00 ➝ $92.00
11/8/2022Morgan StanleyBoost TargetEqual Weight$85.00 ➝ $90.00
11/8/2022Barrington ResearchBoost TargetOutperform$88.00 ➝ $94.00
11/8/2022Raymond James FinancialBoost TargetOutperform$88.00 ➝ $100.00
11/8/2022JMP SecuritiesBoost TargetMarket Outperform$90.00 ➝ $105.00
11/8/2022MizuhoBoost TargetBuy$90.00 ➝ $100.00
11/8/2022CitigroupBoost TargetNeutral$80.00 ➝ $88.00
10/12/2022MizuhoInitiated CoverageBuy$90.00
10/11/2022Morgan StanleyBoost TargetEqual Weight$74.00 ➝ $85.00
10/5/2022CitigroupBoost Target$74.00 ➝ $80.00
8/15/2022CitigroupBoost Target$74.00
8/11/2022Morgan StanleyBoost TargetEqual Weight$70.00 ➝ $74.00
8/11/2022JMP SecuritiesBoost TargetMarket Outperform$80.00 ➝ $90.00
8/11/2022Barrington ResearchBoost TargetOutperform$77.00 ➝ $88.00
8/11/2022Raymond James FinancialBoost TargetOutperform$76.00 ➝ $88.00
7/8/2022JMP SecuritiesReiterated RatingBuy$80.00
7/1/2022Morgan StanleyBoost TargetEqual Weight$60.00 ➝ $70.00
7/1/2022Raymond James FinancialBoost TargetOutperform$63.00 ➝ $76.00
6/2/2022JMP SecuritiesReiterated RatingBuy$80.00
5/11/2022Barrington ResearchBoost Target$71.00 ➝ $77.00
2/9/2022Barrington ResearchReiterated RatingOutperform
2/9/2022Raymond James FinancialLower TargetOutperform$70.00 ➝ $66.00
1/27/2022Needham & Company LLCDowngradeBuy ➝ Hold
1/7/2022Morgan StanleyLower TargetEqual Weight$68.00 ➝ $60.00
12/15/2021CitigroupDowngradeBuy ➝ Neutral$75.00 ➝ $59.00
11/10/2021JMP SecuritiesLower TargetOutperform$90.00 ➝ $80.00
11/10/2021Raymond James FinancialLower TargetOutperform$75.00 ➝ $70.00
6/29/2021Needham & Company LLCReiterated RatingBuy$86.00
6/17/2021CitigroupInitiated CoverageBuy
5/20/2021JMP SecuritiesLower TargetMarket Outperform$110.00 ➝ $90.00
5/14/2021Jefferies Financial GroupLower TargetBuy$105.00 ➝ $85.00
5/14/2021CJS SecuritiesUpgradeMarket Perform ➝ Outperform
5/14/2021Barrington ResearchLower TargetOutperform$91.00 ➝ $71.00
5/14/2021Morgan StanleyLower TargetEqual Weight$83.00 ➝ $75.00
5/14/2021JMP SecuritiesLower TargetOutperform$110.00 ➝ $90.00
4/26/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$147.00 ➝ $83.00
4/20/2021Barrington ResearchLower TargetOutperform$140.00 ➝ $91.00
4/20/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$147.00 ➝ $83.00
4/19/2021Needham & Company LLCLower TargetBuy$158.00 ➝ $108.00
4/19/2021CJS SecuritiesDowngradeOutperform ➝ Market Perform
2/12/2021Raymond James FinancialBoost TargetOutperform$145.00 ➝ $155.00
2/3/2021Morgan StanleyBoost TargetOverweight$139.00 ➝ $147.00
2/3/2021Raymond James FinancialBoost TargetOutperform$135.00 ➝ $145.00
2/3/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$140.00
1/21/2021JMP SecuritiesBoost Target$110.00 ➝ $140.00
1/21/2021Barrington ResearchDowngradeOutperform ➝ Market Perform
1/20/2021Needham & Company LLCBoost TargetBuy$122.00 ➝ $142.00
1/7/2021Raymond James FinancialBoost TargetOutperform$130.00 ➝ $135.00
12/15/2020Morgan StanleyBoost TargetOverweight$110.00 ➝ $139.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 27 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2025
  • 30 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 24 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 27 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 12 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 10 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 30 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 30 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Haemonetics logo
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $83.78
Low: $81.50
High: $84.19

50 Day Range

MA: $61.12
Low: $48.15
High: $83.78

52 Week Range

Now: $83.78
Low: $47.31
High: $85.00

Volume

647,661 shs

Average Volume

1,190,093 shs

Market Capitalization

$3.92 billion

P/E Ratio

24.50

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Haemonetics?

The following equities research analysts have issued research reports on Haemonetics in the last twelve months: Baird R W, Bank of America Corporation, Barrington Research, BTIG Research, Citigroup Inc., JMP Securities, JPMorgan Chase & Co., Mizuho, Needham & Company LLC, Raymond James Financial, Inc., Robert W. Baird, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for HAE.

What is the current price target for Haemonetics?

0 Wall Street analysts have set twelve-month price targets for Haemonetics in the last year. Their average twelve-month price target is $79.70, suggesting a possible downside of 4.9%. JMP Securities has the highest price target set, predicting HAE will reach $100.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $62.00 for Haemonetics in the next year.
View the latest price targets for HAE.

What is the current consensus analyst rating for Haemonetics?

Haemonetics currently has 1 sell rating, 2 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for HAE.

What other companies compete with Haemonetics?

Other companies that are similar to Haemonetics include DexCom, HealthEquity, Lantheus, Insulet and Quanterix. Learn More about companies similar to Haemonetics.

How do I contact Haemonetics' investor relations team?

Haemonetics' physical mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier's listed phone number is (781) 848-7100 and its investor relations email address is [email protected]. The official website for Haemonetics is www.haemonetics.com. Learn More about contacing Haemonetics investor relations.